LEXINGTON, Mass., Oct. 26,
2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of emavusertib, an
orally available, small molecule IRAK4 inhibitor for the treatment
of hematologic malignancies, today announced that the Company will
release its third quarter 2023 financial results on Thursday, November 2, 2023, at 8:00 a.m. ET. Management will host a conference
call on the same day at 8:30 a.m.
ET.
To access the live conference call, please dial (888)-390-0546
from the United States or (416)-764-8688 from other
locations, shortly before 8:30 a.m. ET. The conference call
can also be accessed on the Curis website
at www.curis.com in the 'Investors' section. A replay of
the financial results conference call will be available on the
Curis website shortly after completion of the call.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor
for the treatment of hematologic malignancies. Emavusertib is
currently undergoing testing in the Phase 1/2 TakeAim Lymphoma
study in patients with hematologic malignancies, such as
non-Hodgkin's lymphoma and other B cell malignancies in combination
with the BTK inhibitor ibrutinib, and as a monotherapy in the Phase
1/2 TakeAim Leukemia study in patients with acute myeloid leukemia
and myelodysplastic syndrome, for which it has received Orphan Drug
Designation from the U.S. Food and Drug Administration. Curis,
through its 2015 collaboration with Aurigene, has the exclusive
license to emavusertib (CA-4948). Curis licensed its rights to
Erivedge® to Genentech, a member of the Roche Group, under which
they are commercializing Erivedge® for the treatment of advanced
basal cell carcinoma. For more information, visit Curis's website
at www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-release-third-quarter-2023-financial-results-and-hold-conference-call-on-november-2-2023-301968409.html
SOURCE Curis, Inc.